Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV) -- Ignore unavailable to you. Want to Upgrade?

To: Mao II who wrote (2214)	11/15/1998 12:20:00 PM
From: Douglas	Read Replies (1) \| Respond to of 2836

Some news headlines: cytokine cocktail CelSci licensing offer, USA, Europe. R & D Focus Drug News, 11/16/1998, 199 words. European and US partners are sought by CelSci for the development and marketing of MULTIKINE, a cytokine cocktail, for the treatment of head and neck, prostate and other solid tumors, according to Dr Eyal ... vaccine, malaria, vaccine, tuberculosis, vaccine, herpes simplex virus R & D Focus Drug News, 11/16/1998, 166 words. Partners are sought by CelSci for therapeutic vaccines for the treatment and prevention of herpes simplex virus (HSV) infection, malaria and tuberculosis. Dr Eyal Talor, Senior Vice President, Research ... vaccine, HIV HGP 30 CelSci licensing offer, Worldwide. R & D Focus Drug News, 11/16/1998, 170 words. Development of a therapeutic vaccine for the treatment and prevention of HIV infection is under way at CelSci, according to Dr Eyal Talor, Senior Vice President Research and Manufacturing, at the 6th ... vaccine, HIV HGP 30W CelSci licensing offer, Worldwide. R & D Focus Drug News, 11/16/1998, 240 words. Collaborators are sought by CelSci for the development of HGP 30W, a vaccine with potential for the prevention of infection by most strains and clades of HIV-1. In an interview with R&D focus at the 6th Annual ... LEAPS CelSci licensing offer, Worldwide. R & D Focus Drug News, 11/16/1998, 195 words. Partners are sought by CelSci which possess proprietary disease-associated epitopes or peptide antigens involved in autoimmune disease, allergic asthma or allergy, for the development of vaccines ...